E-resources
Peer reviewed
Open access
-
Tewari, Krishnansu S; Monk, Bradley J; Vergote, Ignace; Miller, Austin; de Melo, Andreia C; Kim, Hee-Seung; Kim, Yong Man; Lisyanskaya, Alla; Samouëlian, Vanessa; Lorusso, Domenica; Damian, Fernanda; Chang, Chih-Long; Gotovkin, Evgeniy A; Takahashi, Shunji; Ramone, Daniella; Pikiel, Joanna; Maćkowiak-Matejczyk, Beata; Guerra Alía, Eva M; Colombo, Nicoletta; Makarova, Yulia; Rischin, Danny; Lheureux, Stephanie; Hasegawa, Kosei; Fujiwara, Keiichi; Li, Jingjin; Jamil, Shaheda; Jankovic, Vladimir; Chen, Chieh-I; Seebach, Frank; Weinreich, David M; Yancopoulos, George D; Lowy, Israel; Mathias, Melissa; Fury, Matthew G; Oaknin, Ana
The New England journal of medicine, 02/2022, Volume: 386, Issue: 6Journal Article
Cervical cancer that relapses after platinum-containing chemotherapy is often refractory to salvage therapy. Cemiplimab, a fully human antibody to PD-1, was compared with single-agent chemotherapy with pemetrexed, gemcitabine, irinotecan, topotecan, or vinorelban. Among 608 patients, median overall survival was 8.5 months with chemotherapy and 12.0 months with cemiplimab.
